| Dr Mark Evan Baker, PHARMD | |
|
2800 Main St, Bridgeport, CT 06606-4201 | |
| (475) 210-6062 | |
| Not Available |
| Full Name | Dr Mark Evan Baker |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 2800 Main St, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598498701 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PCT.0014914 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Evan Baker, PHARMD 50 Cherry St Apt B, Milford, CT 06460-3487 Ph: () - | Dr Mark Evan Baker, PHARMD 2800 Main St, Bridgeport, CT 06606-4201 Ph: (475) 210-6062 |
News Archive
The detection of prions in the blood of patients with variant Creutzfeldt-Jakob disease could lead to a noninvasive diagnosis prior to symptoms and a way to identify prion contamination of the donated blood supply, according to researchers at McGovern Medical School at The University of Texas Health Science Center at Houston.
A discovery made by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at the University of Minnesota has been licensed to a major clinical laboratory for development and could soon result in a test that quickly and easily enables patients and their physicians to determine when a lupus flare is imminent.
Today, at the IFT Annual Meeting and Food Expo, the largest annual food science forum and exposition in the world, Canon Communications LLC announced it is in the process of a redesign of NutritionalOutlook.com, the leading online resource for manufacturers of dietary supplements and healthy foods. The website redesign, featuring new content, qualified supplier search, community-building tools, and nutraceutical industry resources, will launch in fall 2010.
BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
› Verified 6 days ago
Dr. Yeganeh Ragati Haghi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1060 E Main St, Bridgeport, CT 06608 Phone: 203-382-0009 | |
Yujin Hong, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4531 Main St, Bridgeport, CT 06606 Phone: 203-372-6538 Fax: 844-411-6470 | |
Ju-sung Song, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 960 North Ave, Bridgeport, CT 06606 Phone: 203-334-6978 | |
Dr. Lena Devietro, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 267 Grant St, Bridgeport, CT 06610 Phone: 203-384-3252 | |
Paul Joseph Piazza, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 267 Grant St, Bridgeport, CT 06610 Phone: 203-384-3252 Fax: 203-384-3625 | |
Dr. Lauren Michelle Dietrich, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2800 Main St, Bridgeport, CT 06606 Phone: 203-576-6227 | |
Kevin Ehl, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1000 Park Ave, Bridgeport, CT 06604 Phone: 203-696-0127 |